BCIQ Profiles

Company Profile Report
0303 FogPharma series C
BioCentury & Getty Images

Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

Mar 3, 2021 | 5:27 PM GMT

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the

Read the full 484 word article

How to gain access

Continue reading with a
two-week free trial.